Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification

[1]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[2]  Ying Tang,et al.  LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth , 2014, Clinical Cancer Research.

[3]  C. Hofmeister,et al.  Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma , 2014, British Journal of Cancer.

[4]  P. LoRusso,et al.  Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors. , 2014 .

[5]  C. Sheridan.  Genentech to salvage anti-MET antibody with subgroup analysis , 2014, Nature Biotechnology.

[6]  N. Zhao,et al.  c-Met as a Prognostic Marker in Gastric Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.

[7]  Shinji Yamazaki,et al.  Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor , 2012, Molecular Cancer Therapeutics.

[8]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[9]  G. V. Vande Woude,et al.  Structural basis for agonism and antagonism of hepatocyte growth factor , 2010, Proceedings of the National Academy of Sciences.

[10]  G. Forte,et al.  Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis. , 2010, American journal of physiology. Heart and circulatory physiology.

[11]  J. Christensen,et al.  Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. , 2009, Biochemistry.

[12]  C. Bailly,et al.  Abstract #835: First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: I) in vitro mechanism of action , 2009 .

[13]  F. Barany,et al.  c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. , 2008, Cancer letters.

[14]  J. Fueller,et al.  C-RAF activation promotes BAD poly-ubiquitylation and turn-over by the proteasome. , 2008, Biochemical and biophysical research communications.

[15]  S. Watowich,et al.  Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation. , 2008, Biochemistry.

[16]  G. V. Vande Woude,et al.  Showering c-MET-dependent cancers with drugs. , 2008, Current opinion in genetics & development.

[17]  I. Kasman,et al.  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.

[18]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[19]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Christensen,et al.  A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin , 2005, Clinical Cancer Research.

[21]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[22]  M. Matsuda,et al.  Cloning of a cancer cell-producing hepatocyte growth factor, vascular endothelial growth factor, and interleukin-8 from gastric cancer cells , 2003, In Vitro Cellular & Developmental Biology - Animal.

[23]  T. Hirao,et al.  The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 1999, Cancer.

[24]  P. Comoglio,et al.  Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. , 1998, Journal of cell science.

[25]  H. Ito,et al.  Frequent amplification of the c-met gene in scirrhous type stomach cancer. , 1992, Biochemical and biophysical research communications.

[26]  R. Porter.  Structural Studies of Immunoglobulins , 1973, Science.

[27]  L. Goetsch,et al.  Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. , 2013, Frontiers in bioscience.

[28]  R. Porter.  Lecture for the Nobel Prize for physiology or medicine 1972: Structural studies of immunoglobulins. 1972. , 1991, Scandinavian journal of immunology.

[29]  G. Edelman,et al.  The Nobel lectures in immunology : the Nobel prize for physiology or medicine, 1972 , 1991 .